

# Sunil Krishnan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3037081/publications.pdf>

Version: 2024-02-01

306  
papers

17,778  
citations

8159

76  
h-index

16127

124  
g-index

322  
all docs

322  
docs citations

322  
times ranked

24291  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Investigation of miRNA Biomarkers as Chemoresistance Regulators in Melanoma: A Protocol for Systematic Review and Meta-Analysis. <i>Genes</i> , 2022, 13, 115.	1.0	1
2	NBS1-CtIP-mediated DNA end resection suppresses cGAS binding to micronuclei. <i>Nucleic Acids Research</i> , 2022, 50, 2681-2699.	6.5	8
3	COVID-19 Outcomes in Patients Hospitalised with Acute Myocardial Infarction (AMI): A Protocol for Systematic Review and Meta-Analysis. <i>Covid</i> , 2022, 2, 138-147.	0.7	4
4	Mapping Research on miRNAs in Cancer: A Global Data Analysis and Bibliometric Profiling Analysis. <i>Pathophysiology</i> , 2022, 29, 66-80.	1.0	3
5	A Clinical Investigation on the Theragnostic Effect of MicroRNA Biomarkers for Survival Outcome in Cervical Cancer: A PRISMA-P Compliant Protocol for Systematic Review and Comprehensive Meta-Analysis. <i>Genes</i> , 2022, 13, 463.	1.0	4
6	Transforming Nuclear Medicine with Nanoradiopharmaceuticals. <i>ACS Nano</i> , 2022, 16, 5036-5061.	7.3	30
7	Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3892-3897.	3.3	17
8	Bibliometric and Density Visualisation Mapping Analysis of Domestic Violence in Australia Research Output 1984-2019. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4837.	1.2	1
9	3JC48-3 (methyl 4-(2-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth. <i>Cancer Gene Therapy</i> , 2022, 29, 1550-1557.	2.2	4
10	ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. <i>Science Immunology</i> , 2022, 7, .	5.6	52
11	Synthesis and characterization of gadolinium-decorated [60]fullerene for tumor imaging and radiation sensitization. <i>International Journal of Radiation Biology</i> , 2021, 97, 1129-1139.	1.0	4
12	Technological Advances in Radiotherapy. , 2021, , 73-91.		0
13	Prognostic Significance of Neutrophil to Lymphocyte Ratio Dynamics in Patients with Hepatocellular Carcinoma Treated with Radioembolization Using Glass Microspheres. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2624-2634.	3.3	10
14	A Systematic Review and Meta-Analysis of Cancer Patients Affected by a Novel Coronavirus. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa102.	1.4	81
15	Boron Neutron Capture Therapy: A Review of Clinical Applications. <i>Frontiers in Oncology</i> , 2021, 11, 601820.	1.3	118
16	Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 57-69.	1.8	21
17	Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. <i>Cancer Letters</i> , 2021, 502, 180-188.	3.2	35
18	MRI Staging in an Evolving Management Paradigm for Rectal Cancer, From the <i>AJR</i> Special Series on Cancer Staging. <i>American Journal of Roentgenology</i> , 2021, 217, 1282-1293.	1.0	7

#	ARTICLE	IF	CITATIONS
19	Real versus simulated galactic cosmic radiation for investigating cancer risk in the hematopoietic system - are we comparing apples to apples?. <i>Life Sciences in Space Research</i> , 2021, 29, 8-14.	1.2	5
20	Intensity Modulated Proton Therapy for Hepatocellular Carcinoma: Initial Clinical Experience. <i>Advances in Radiation Oncology</i> , 2021, 6, 100675.	0.6	11
21	Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer. <i>Cancers</i> , 2021, 13, 3642.	1.7	6
22	Prognostic Utility of Plateletâ€“Lymphocyte Ratio, Neutrophilâ€“Lymphocyte Ratio and Monocyteâ€“Lymphocyte Ratio in Head and Neck Cancers: A Detailed PRISMA Compliant Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 4166.	1.7	51
23	High-Content Clonogenic Survival Screen to Identify Chemoradiation Sensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e27-e37.	0.4	5
24	A Clinical Update on the Prognostic Effect of microRNA Biomarkers for Survival Outcome in Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 4369.	1.7	8
25	Preclinical Risk Evaluation of Normal Tissue Injury With Novel Radiosensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e54-e62.	0.4	7
26	Stability of MRI contrast agents in high-energy radiation of a 1.5T MR-Linac. <i>Radiotherapy and Oncology</i> , 2021, 161, 55-64.	0.3	12
27	Carbon Ion Radiotherapy in the Management of Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1169-1179.	1.8	4
28	Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo-radiation. <i>Redox Biology</i> , 2021, 47, 102132.	3.9	17
29	Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2021, 12, 2075-2088.	0.8	11
30	Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair. <i>Nucleic Acids Research</i> , 2021, 49, 11067-11082.	6.5	26
31	Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa103.	1.4	15
32	CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer. <i>Nanoscale</i> , 2021, 13, 19056-19065.	2.8	7
33	Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1131-1139.	0.4	5
34	Meta-Analysis of Definitive Photon and Particle Irradiation for Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e56.	0.4	1
35	Heavy Ion Minibeam Therapy: Side Effects in Normal Brain. <i>Cancers</i> , 2021, 13, 6207.	1.7	2
36	Clinical Theragnostic Relationship between Chemotherapeutic Resistance, and Sensitivity and miRNA Expressions in Head and Neck Cancers: A Systematic Review and Meta-Analysis Protocol. <i>Genes</i> , 2021, 12, 2029.	1.0	3

#	ARTICLE	IF	CITATIONS
37	IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 369-376.	0.6	5
38	Visible-Light-Activated Molecular Nanomachines Kill Pancreatic Cancer Cells. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 410-417.	4.0	24
39	Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models. <i>International Journal of Pharmaceutics: X</i> , 2020, 2, 100056.	1.2	8
40	Pilot study of neurologic toxicity in mice after proton minibeam therapy. <i>Scientific Reports</i> , 2020, 10, 11368.	1.6	5
41	Immunogenicity of Externally Activated Nanoparticles for Cancer Therapy. <i>Cancers</i> , 2020, 12, 3559.	1.7	6
42	Cancer research, treatment, and COVID-19. <i>Cancer Nanotechnology</i> , 2020, 11, 7.	1.9	0
43	Immunomodulatory Effects of Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8151.	1.8	34
44	Roadmap for metal nanoparticles in radiation therapy: current status, translational challenges, and future directions. <i>Physics in Medicine and Biology</i> , 2020, 65, 21RM02.	1.6	101
45	A systematic review of the role of carbon ion radiation therapy in recurrent rectal cancer. <i>Acta Oncologica</i> , 2020, 59, 1218-1223.	0.8	8
46	Clinical Theragnostic Potential of Diverse miRNA Expressions in Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 1199.	1.7	20
47	P-130 Short course pelvic radiotherapy for localized and oligometastatic rectal adenocarcinoma: The Mayo Clinic experience. <i>Annals of Oncology</i> , 2020, 31, S132.	0.6	0
48	Carbon Ion Radiotherapy in the Treatment of Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 737-743.	0.5	5
49	Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020, 12, 1808.	1.7	13
50	Molecular Nanomachines Can Destroy Tissue or Kill Multicellular Eukaryotes. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 13657-13670.	4.0	16
51	Virologic Impact of Radiotherapy in Hepatitis C Virus-Infected Patients With Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 72, 775-777.	3.6	4
52	Prognostic Value of MicroRNAs in Stage II Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 15-30.	1.6	8
53	Carbon ion radiation therapy in breast cancer: a new frontier. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 291-296.	1.1	14
54	Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2020, 19, 116-122.	1.0	1

#	ARTICLE	IF	CITATIONS
55	Proton minibeamâ€”a springboard for physics, biology and clinical creativity. <i>British Journal of Radiology</i> , 2020, 93, 20190332.	1.0	1
56	A Mail Audit Independent Peer Review System for Dosimetry Verification of a Small Animal Irradiator. <i>Radiation Research</i> , 2020, 193, 341.	0.7	5
57	Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. <i>Oncotarget</i> , 2020, 11, 1186-1201.	0.8	27
58	Nanoparticles for Stem Cell Therapy Bioengineering in Glioma. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 558375.	2.0	13
59	Carbon Ion Therapy: A Modern Review of an Emerging Technology. <i>Frontiers in Oncology</i> , 2020, 10, 82.	1.3	140
60	Estimating the Number of Patients Eligible for Carbon Ion Radiotherapy in the United States. <i>International Journal of Particle Therapy</i> , 2020, 7, 31-41.	0.9	7
61	The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective. <i>Nanoscale</i> , 2019, 11, 17157-17178.	2.8	59
62	Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis. <i>Cells</i> , 2019, 8, 772.	1.8	33
63	Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986485.	1.4	11
64	miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 900.	1.7	23
65	Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis. <i>Cells</i> , 2019, 8, 1250.	1.8	33
66	Boron-Nanoparticle-Loaded Folic-Acid-Functionalized Liposomes to Achieve Optimum Boron Concentration for Boron Neutron Capture Therapy of Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2019, 15, 1714-1723.	0.5	30
67	Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registrationâ€”based image guidance. <i>Radiation Oncology</i> , 2019, 14, 154.	1.2	8
68	IL-15 Rescues Lymphopenia and Adverse Tumor Control Outcomes Following Splenic Radiation in Murine Pancreatic Cancer Models. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E248-E249.	0.4	0
69	Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies. <i>Clinical and Translational Radiation Oncology</i> , 2019, 19, 59-65.	0.9	17
70	Patient Setup Management for Pancreatic SBRT: Daily CT Based Assessment of Setup Accuracy using Vertebral Bone, Fiducial Markers, Biliary Stent, and Soft-Tissue Targeting. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E770.	0.4	1
71	Harnessing the Differential Immune Signature of High Versus Low Linear Energy Transfer Protons to Elicit Potent Systemic Immune Responses in Colorectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E667-E668.	0.4	0
72	Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2381-2393.	1.9	22

#	ARTICLE	IF	CITATIONS
73	Biomarkers of radiation-induced vascular injury. <i>Cancer Reports</i> , 2019, 2, e1152.	0.6	8
74	Evaluation of dose point kernel rescaling methods for nanoscale dose estimation around gold nanoparticles using Geant4 Monte Carlo simulations. <i>Scientific Reports</i> , 2019, 9, 3583.	1.6	10
75	Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 73-86.	0.4	41
76	Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 133, 54-61.	0.3	37
77	Merging Orthovoltage X-Ray Minibeams spare the proximal tissues while producing a solid beam at the target. <i>Scientific Reports</i> , 2019, 9, 1198.	1.6	11
78	A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	11
79	Enhancing Colorectal Cancer Radiation Therapy Efficacy using Silver Nanoprisms Decorated with Graphene as Radiosensitizers. <i>Scientific Reports</i> , 2019, 9, 17120.	1.6	34
80	Ultra high dose rate (35â€‰%Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome. <i>Scientific Reports</i> , 2019, 9, 17180.	1.6	66
81	YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer â€œ Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2264-2277.	3.2	49
82	Differences in nativity, age and gender may impact health behavior and perspectives among Asian Indians. <i>Ethnicity and Health</i> , 2019, 24, 484-494.	1.5	2
83	High-sensitivity imaging and quantification of intratumoral distributions of gold nanoparticles using a benchtop x-ray fluorescence imaging system. <i>Optics Letters</i> , 2019, 44, 5314.	1.7	7
84	Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. <i>Oncotarget</i> , 2019, 10, 4703-4718.	0.8	6
85	Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1069-1077.	1.9	27
86	A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 42-51.	2.0	218
87	Quantitative Electrochemical DNA Microarray on a Monolith Electrode with Ten Attomolar Sensitivity, 100â€‰% Specificity, and Zero Background. <i>ChemElectroChem</i> , 2018, 5, 429-433.	1.7	8
88	Radiation therapy and immunotherapy: what is the optimal timing or sequencing?. <i>Immunotherapy</i> , 2018, 10, 299-316.	1.0	49
89	Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. <i>Cancer</i> , 2018, 124, 1701-1709.	2.0	35
90	Supramolecular Nanofibers of Curcumin for Highly Amplified Radiosensitization of Colorectal Cancers to Ionizing Radiation. <i>Advanced Functional Materials</i> , 2018, 28, 1707140.	7.8	65

#	ARTICLE	IF	CITATIONS
91	Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. <i>Radiotherapy and Oncology</i> , 2018, 128, 154-160.	0.3	109
92	Harnessing and Optimizing the Interplay between Immunotherapy and Radiotherapy to Improve Survival Outcomes. <i>Molecular Cancer Research</i> , 2018, 16, 1209-1214.	1.5	7
93	High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 584-590.	0.3	58
94	Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 632-637.	0.6	14
95	Radiosensitization by inhibiting DNA repair: Turning the spotlight on homologous recombination. <i>Hepatology</i> , 2018, 67, 470-472.	3.6	3
96	Recent advances in radiation therapy of pancreatic cancer. <i>F1000Research</i> , 2018, 7, 1931.	0.8	12
97	A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors. <i>Annals of Oncology</i> , 2018, 29, viii411.	0.6	8
98	Radiation-Induced Endothelial Vascular Injury. <i>JACC Basic To Translational Science</i> , 2018, 3, 563-572.	1.9	177
99	Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 102-108.	0.4	19
100	Imaging predictors of treatment outcomes in rectal cancer: An overview. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 153-162.	2.0	17
101	Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. <i>Clinical Cancer Research</i> , 2018, 24, 3500-3509.	3.2	3
102	Ionizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 23.	1.1	17
103	Developing a Reliable Mouse Model for Cancer Therapy-Induced Cardiovascular Toxicity in Cancer Patients and Survivors. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 26.	1.1	7
104	Gold-Small Interfering RNA as Optically Responsive Nanostructures for Cancer Theranostics. <i>Journal of Biomedical Nanotechnology</i> , 2018, 14, 809-828.	0.5	10
105	Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. <i>Advances in Radiation Oncology</i> , 2018, 3, 595-600.	0.6	4
106	(P16) Hyperfractionated Abdominal Reirradiation for Gastrointestinal Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, E27.	0.4	0
107	Hypoxia-targeted gold nanorods for cancer photothermal therapy. <i>Oncotarget</i> , 2018, 9, 26556-26571.	0.8	24
108	Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 163-166.	0.6	24

#	ARTICLE	IF	CITATIONS
109	Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 277-282.	0.6	20
110	Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 555-560.	0.6	18
111	Gold nanotriangles: scale up and X-ray radiosensitization effects in mice. Nanoscale, 2017, 9, 5085-5093.	2.8	58
112	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiotherapy and Oncology, 2017, 122, 146-151.	0.3	45
113	Real-time liver uptake and biodistribution of magnetic nanoparticles determined by AC biosusceptometry. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1519-1529.	1.7	34
114	Mitochondrion-anchoring Photosensitizer with Aggregation-induced Emission Characteristics Synergistically Boosts the Radiosensitivity of Cancer Cells to Ionizing Radiation. Advanced Materials, 2017, 29, 1606167.	11.1	222
115	Radiosensitizers: Mitochondrion-anchoring Photosensitizer with Aggregation-induced Emission Characteristics Synergistically Boosts the Radiosensitivity of Cancer Cells to Ionizing Radiation (Adv.) Tj ETQq1 1 0.784314 rgBT /Over		
116	Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Advances in Radiation Oncology, 2017, 2, 455-464.	0.6	18
117	In Reply to Yazici et al. International Journal of Radiation Oncology Biology Physics, 2017, 98, 485-486.	0.4	3
118	The Rise of Radiomics and Implications for Oncologic Management. Journal of the National Cancer Institute, 2017, 109, .	3.0	104
119	Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Advances in Radiation Oncology, 2017, 2, 403-415.	0.6	29
120	Development of Wnt/Notch Activators as Mitigators of Acute Radiation Gastrointestinal Syndrome. International Journal of Radiation Oncology Biology Physics, 2017, 99, S20.	0.4	1
121	Targeted Gold Nanoparticles Enhance Radiation Effects in Pancreatic Tumor Models. International Journal of Radiation Oncology Biology Physics, 2017, 99, E574-E575.	0.4	1
122	Radiosensitization of triple negative breast cancer with gold nanosphere conjugates targeting the folate receptor. International Journal of Radiation Oncology Biology Physics, 2017, 99, E579-E580.	0.4	0
123	Orthovoltage X-Ray Minibeam Therapy of Moving Targets. International Journal of Radiation Oncology Biology Physics, 2017, 99, E731-E732.	0.4	1
124	Targeting Multiple Liver Segments, Including the Entire Right Lobe, With Ablative Radiation Therapy as Salvage Therapy for Patients With Colorectal Liver Metastases Not Eligible for Two-Stage Hepatectomy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E160-E161.	0.4	0
125	A Bi-institutional Experience of Definitive Chemoradiation Therapy for Treatment of Anal Cancer Involving the Para-aortic Lymph Nodes. International Journal of Radiation Oncology Biology Physics, 2017, 99, E165-E166.	0.4	0
126	Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. Clinical and Translational Radiation Oncology, 2017, 4, 39-45.	0.9	11



#	ARTICLE	IF	CITATIONS
127	&lt;em&gt;En Face&lt;/em&gt; Preparation of Mouse Blood Vessels. Journal of Visualized Experiments, 2017, , .	0.2	16
128	(S021) A Phase 2 Randomized Double Blinded Study Evaluating the Efficacy of Curcumin With Pre-Operative Chemoradiation for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, E7.	0.4	2
129	Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2017, 97, 323-332.	0.4	85
130	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Research, 2017, 77, 839-850.	0.4	195
131	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Journal of Gastrointestinal Surgery, 2017, 21, 164-174.	0.9	124
132	Radiosensitization of Prostate Cancers In Vitro and In Vivo to Erbium-filtered Orthovoltage X-rays Using Actively Targeted Gold Nanoparticles. Scientific Reports, 2017, 7, 18044.	1.6	38
133	Radiation-Induced Cardiovascular Disease: A Clinical Perspective. Frontiers in Cardiovascular Medicine, 2017, 4, 66.	1.1	84
134	Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. Journal of Gastrointestinal Oncology, 2017, 8, 990-997.	0.6	19
135	Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. PLoS ONE, 2017, 12, e0171985.	1.1	25
136	Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging. PLoS ONE, 2017, 12, e0185116.	1.1	24
137	Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget, 2017, 8, 28696-28710.	0.8	16
138	Spatial habitats from multiparametric MR imaging are associated with signaling pathway activities and survival in glioblastoma. Oncotarget, 2017, 8, 112992-113001.	0.8	21
139	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer, 2016, 122, 2671-2679.	2.0	49
140	Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. Journal of the National Cancer Institute, 2016, 108, djw133.	3.0	79
141	Nanochannel Implants for Minimally-Invasive Insertion and Intratumoral Delivery. Journal of Biomedical Nanotechnology, 2016, 12, 1907-1915.	0.5	21
142	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-Î²-Catenin Signaling in Colorectal Cancer. EBioMedicine, 2016, 13, 113-124.	2.7	106
143	Quantitative imaging of gold nanoparticle distribution in a tumor-bearing mouse using benchtop x-ray fluorescence computed tomography. Scientific Reports, 2016, 6, 22079.	1.6	117
144	Magnetic nanoparticle-induced hyperthermia with appropriate payloads: Paul Ehrlichâ€™s â€œmagic (nano)bulletâ€•for cancer theranostics?. Cancer Treatment Reviews, 2016, 50, 217-227.	3.4	79

#	ARTICLE	IF	CITATIONS
145	Proton Therapy Outcomes for Localized, Unresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, E181-E182.	0.4	1
146	Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. Seminars in Radiation Oncology, 2016, 26, 320-337.	1.0	21
147	Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy: A novel treatment option for unresectable liver tumors. European Journal of Surgical Oncology, 2016, 42, 1591-1596.	0.5	8
148	Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer, 2016, 122, 3838-3847.	2.0	289
149	Current Insights in Radiation Combination Therapies: Influence of Omics and Novel Targeted Agents in Defining New Concepts in Radiation Biology and Clinical Radiation Oncology. Seminars in Radiation Oncology, 2016, 26, 251-253.	1.0	7
150	Enhancing the Relative Biological Effectiveness of Proton Therapy Using EGFR-Targeted Gold Nanorods. International Journal of Radiation Oncology Biology Physics, 2016, 96, S236-S237.	0.4	2
151	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Journal of Gastrointestinal Surgery, 2016, 20, 1975-1985.	0.9	42
152	Hyperthermia using nanoparticles – Promises and pitfalls. International Journal of Hyperthermia, 2016, 32, 76-88.	1.1	158
153	Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing. International Journal of Radiation Oncology Biology Physics, 2016, 95, 120-130.	0.4	117
154	Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2016, 94, 755-765.	0.4	285
155	Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer. Clinical Cancer Research, 2016, 22, 1834-1836.	3.2	5
156	Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?. Nature Reviews Clinical Oncology, 2016, 13, 516-524.	12.5	288
157	Quantitative investigation of physical factors contributing to gold nanoparticle-mediated proton dose enhancement. Physics in Medicine and Biology, 2016, 61, 2562-2581.	1.6	38
158	PDL1 Regulation by p53 via miR-34. Journal of the National Cancer Institute, 2016, 108, .	3.0	475
159	Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization. International Journal of Radiation Oncology Biology Physics, 2016, 94, 189-205.	0.4	182
160	Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS ONE, 2016, 11, e0156910.	1.1	8
161	Radiomics in cancer diagnosis, cancer staging, and prediction of response to treatment. Translational Cancer Research, 2016, 5, 337-339.	0.4	9
162	SU-F-T-666: Molecular-Targeted Gold Nanorods Enhances the RBE of Proton Therapy. Medical Physics, 2016, 43, 3617-3617.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Zerumbone increases oxidative stress in a thiolâ€dependent <sc>ROS</sc>â€independent manner to increase <sc>DNA</sc> damage and sensitize colorectal cancer cells to radiation. <i>Cancer Medicine</i> , 2015, 4, 278-292.	1.3	51
164	HER2/neu-directed therapy for biliary tract cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 58.	6.9	191
165	Charged Particle Therapy with Mini-Segmented Beams. <i>Frontiers in Oncology</i> , 2015, 5, 269.	1.3	21
166	Vitamin E Analogs as Radiation Response Modifiers. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-16.	0.5	26
167	Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1277-1283.	1.7	157
168	Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. <i>Acta OncolÃ³gica</i> , 2015, 54, 971-978.	0.8	47
169	Technology for Innovation in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 485-492.	0.4	58
170	Minibeam Therapy With Protons and Light Ions: Physical Feasibility and Potential to Reduce Radiation Side Effects and to Facilitate Hypofractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 469-474.	0.4	46
171	Quality of life after intensity-modulated radiation therapy for anal cancer. <i>Journal of Radiation Oncology</i> , 2015, 4, 291-298.	0.7	7
172	Radiotherapy-Induced Malfunction in Contemporary Cardiovascular Implantable Electronic Devices. <i>JAMA Oncology</i> , 2015, 1, 624.	3.4	91
173	Potential Applications of Nanoparticles for Hyperthermia. <i>Heat Shock Proteins</i> , 2015, , 197-216.	0.2	0
174	Ablative Radiation Therapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, S113.	0.4	0
175	In Reply to Sahadevan. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1164-1165.	0.4	4
176	SUâ€Eâ€Tâ€46: A Monte Carlo Investigation of Radiation Interactions with Gold Nanoparticles in Water for 6 MV, 85 KeV and 40 KeV Photon Beams. <i>Medical Physics</i> , 2015, 42, 3341-3341.	1.6	0
177	The evolving evidence for the efficacy and safety of charged particle therapy for hepatocellular carcinoma-a commentary. <i>Annals of Translational Medicine</i> , 2015, 3, 364.	0.7	0
178	Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	28
179	Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Anal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 461-466.	0.6	65
180	The Rare Cancer Network: Ongoing Studies and Future Strategy. <i>Rare Tumors</i> , 2014, 6, 91-94.	0.3	8

#	ARTICLE	IF	CITATIONS
181	Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 301-305.	0.4	21
182	Gold nanoparticles in breast cancer treatment: Promise and potential pitfalls. <i>Cancer Letters</i> , 2014, 347, 46-53.	3.2	205
183	Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?. <i>Cancer Immunology Research</i> , 2014, 2, 831-838.	1.6	270
184	Interobserver Variability in Target Definition for Hepatocellular Carcinoma With and Without Portal Vein Thrombus: Radiation Therapy Oncology Group Consensus Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 804-813.	0.4	33
185	Design of an Yb-169 source optimized for gold nanoparticle-aided radiation therapy. <i>Medical Physics</i> , 2014, 41, 101709.	1.6	11
186	Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. <i>Hpb</i> , 2014, 16, 430-438.	0.1	151
187	Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells. <i>Nanomedicine</i> , 2014, 9, 1209-1222.	1.7	62
188	SU-E-T-231: Measurements of Gold Nanoparticle-Mediated Proton Dose Enhancement Due to Particle-Induced X-Ray Emission and Activation Products Using Radiochromic Films and CdTe Detector. <i>Medical Physics</i> , 2014, 41, 276-276.	1.6	0
189	TH-E-BRD-01: Innovation in (gold) Nanoparticle-Enhanced Therapy. <i>Medical Physics</i> , 2014, 41, 568-568.	1.6	0
190	Development and validation of a sensitive LC/MS/MS method for the determination of $^{13}\text{C}$ -tocotrienol in rat plasma: application to pharmacokinetic studies. <i>Biomedical Chromatography</i> , 2013, 27, 58-66.	0.8	6
191	KRAS Mutations and Rectal Cancer Response to Chemoradiation: Are We Closer to Personalization of Therapy?. <i>Annals of Surgical Oncology</i> , 2013, 20, 3359-3362.	0.7	5
192	Is CA19-9 Response Following Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer an Early Surrogate for Eventual Survival Outcomes?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, S312.	0.4	0
193	Duodenal Toxicity After Fractionated Chemoradiation for Unresectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, e143-e149.	0.4	84
194	Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. <i>Practical Radiation Oncology</i> , 2013, 3, 344-348.	1.1	4
195	Prevention and Treatment of Colorectal Cancer by Natural Agents from Mother Nature. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 37-56.	1.0	56
196	Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. <i>Cancer</i> , 2013, 119, 4231-4241.	2.0	52
197	Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. <i>Journal of the National Cancer Institute</i> , 2013, 105, 686-693.	3.0	40
198	Metformin use and improved response to therapy in rectal cancer. <i>Cancer Medicine</i> , 2013, 2, 99-107.	1.3	85

#	ARTICLE	IF	CITATIONS
199	4D and multi-phase breath-hold CT imaging with synchronized intravenous contrast injection for liver tumor delineation. , 2013, , .		0
200	Intensifying local radiotherapy for pancreatic cancer-who benefits and how do we select them?. Journal of Gastrointestinal Oncology, 2013, 4, 337-9.	0.6	5
201	Convergence of nanotechnology with radiation therapy-insights and implications for clinical translation. Translational Cancer Research, 2013, 2, 256-268.	0.4	26
202	Bioconjugated Magnetic Nanoparticles Effectively Target Breast Cancer Cells for External Thermal Enhancement. International Journal of Radiation Oncology Biology Physics, 2012, 84, S691-S692.	0.4	0
203	Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer. Journal of Clinical Oncology, 2012, 30, 1770-1776.	0.8	427
204	Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients. Radiotherapy and Oncology, 2012, 104, 161-166.	0.3	31
205	Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain, Behavior, and Immunity, 2012, 26, 699-705.	2.0	94
206	Liver Cancer. , 2012, , 95-119.		0
207	In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy. International Journal of Nanomedicine, 2012, 7, 1251.	3.3	96
208	Narrow band imaging of squamous cell carcinoma tumors using topically delivered anti-EGFR antibody conjugated gold nanorods. Lasers in Surgery and Medicine, 2012, 44, 310-317.	1.1	27
209	Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. International Journal of Cancer, 2012, 131, E292-303.	2.3	46
210	Ursolic Acid Inhibits Growth and Metastasis of Human Colorectal Cancer in an Orthotopic Nude Mouse Model by Targeting Multiple Cell Signaling Pathways: Chemosensitization with Capecitabine. Clinical Cancer Research, 2012, 18, 4942-4953.	3.2	152
211	Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. International Journal of Cancer, 2012, 130, 2176-2184.	2.3	89
212	Recurrent invasive lobular carcinoma presenting as a ruptured breast implant. Radiology and Oncology, 2012, 46, 23-7.	0.6	3
213	Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol <sup>3</sup> gica, 2011, 50, 1191-1198.	0.8	19
214	Comparative analysis of volumetric modulated arc therapy versus intensity modulated radiation therapy for radiotherapy of anal carcinoma. Practical Radiation Oncology, 2011, 1, 163-172.	1.1	8
215	Risk Factors for Gastrointestinal Bleeding in Patients Treated with Radiation Therapy for Intrahepatic Cholangiocarcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, S354.	0.4	0
216	Phase I Trial of Preoperative Radiation Therapy with Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, S96-S97.	0.4	0

#	ARTICLE	IF	CITATIONS
217	Integrin $\alpha_5\beta_3$ -targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. <i>International Journal of Nanomedicine</i> , 2011, 6, 259.	3.3	63
218	Charged-Particle Therapy for Hepatocellular Carcinoma. <i>Seminars in Radiation Oncology</i> , 2011, 21, 278-286.	1.0	55
219	Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. <i>Cancer</i> , 2011, 117, 3713-3722.	2.0	51
220	HIF-1 $\alpha$ -Dependent Stromal Adaptation to Ischemia Mediates <i>In Vivo</i> Tumor Radiation Resistance. <i>Molecular Cancer Research</i> , 2011, 9, 259-270.	1.5	24
221	Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of <i>Smad4(Dpc4)</i> Immunostaining With Pattern of Disease Progression. <i>Journal of Clinical Oncology</i> , 2011, 29, 3037-3043.	0.8	267
222	Nanoparticle-mediated hyperthermia in cancer therapy. <i>Therapeutic Delivery</i> , 2011, 2, 1001-1014.	1.2	346
223	Combined Hyperthermia and Radiotherapy for the Treatment of Cancer. <i>Cancers</i> , 2011, 3, 3799-3823.	1.7	88
224	Clinical and Prognostic Implications of Plasma Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Patients With Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3892-3899.	0.8	119
225	Dose-escalated external beam radiotherapy in unresectable hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 267-267.	0.8	0
226	Inhibition of Radiation-Induced DNA Repair and Prosurvival Pathways Contributes to Vorinostat-Mediated Radiosensitization of Pancreatic Cancer Cells. <i>Pancreas</i> , 2010, 39, 1277-1283.	0.5	16
227	Local Excision After Preoperative Chemoradiation Results in an Equivalent Outcome to Total Mesorectal Excision in Selected Patients with T3 Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 441-447.	0.7	107
228	Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 2863-2869.	0.7	100
229	Targeting inflammatory pathways for tumor radiosensitization. <i>Biochemical Pharmacology</i> , 2010, 80, 1904-1914.	2.0	129
230	Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine <i>in vitro</i> and in orthotopic mouse model of human pancreatic cancer. <i>International Journal of Cancer</i> , 2010, 127, 257-268.	2.3	179
231	Plumbagin inhibits proliferative and inflammatory responses of T cells independent of ROS generation but by modulating intracellular thiols. <i>Journal of Cellular Biochemistry</i> , 2010, 110, 1082-1093.	1.2	91
232	Intraorgan biodistribution of gold nanoparticles using intrinsic two-photon-induced photoluminescence. <i>Lasers in Surgery and Medicine</i> , 2010, 42, 630-639.	1.1	38
233	Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. <i>Hpb</i> , 2010, 12, 313-320.	0.1	68
234	Escin, a Pentacyclic Triterpene, Chemosensitizes Human Tumor Cells through Inhibition of Nuclear Factor- $\kappa$ B Signaling Pathway. <i>Molecular Pharmacology</i> , 2010, 77, 818-827.	1.0	59

#	ARTICLE	IF	CITATIONS
235	Î³-Tocotrienol Inhibits Pancreatic Tumors and Sensitizes Them to Gemcitabine Treatment by Modulating the Inflammatory Microenvironment. <i>Cancer Research</i> , 2010, 70, 8695-8705.	0.4	124
236	Sesamin Manifests Chemopreventive Effects through the Suppression of NF-Î²Bâ€“Regulated Cell Survival, Proliferation, Invasion, and Angiogenic Gene Products. <i>Molecular Cancer Research</i> , 2010, 8, 751-761.	1.5	107
237	Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma. <i>Physics in Medicine and Biology</i> , 2010, 55, 7055-7065.	1.6	45
238	Nanoparticle-mediated thermal therapy: Evolving strategies for prostate cancer therapy. <i>International Journal of Hyperthermia</i> , 2010, 26, 775-789.	1.1	122
239	Gadolinium Chloride Augments Tumor-Specific Imaging of Targeted Quantum Dots <i>In Vivo</i> . <i>ACS Nano</i> , 2010, 4, 4131-4141.	7.3	52
240	A Novel Small-Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer Growth <i>In vitro</i> and <i>In vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1136-1146.	1.9	153
241	Thermal Enhancement with Optically Activated Gold Nanoshells Sensitizes Breast Cancer Stem Cells to Radiation Therapy. <i>Science Translational Medicine</i> , 2010, 2, 55ra79.	5.8	167
242	Estimation of microscopic dose enhancement factor around gold nanoparticles by Monte Carlo calculations. <i>Medical Physics</i> , 2010, 37, 3809-3816.	1.6	206
243	SU-GG-T-585: The Impact of Free Breathing versus Average 4D CT Image Data on External Beam Radiotherapy Planning for Liver Tumors. <i>Medical Physics</i> , 2010, 37, 3322-3322.	1.6	0
244	Predicting, preventing, treating and understanding radiation nephropathy. <i>Journal of Gastrointestinal Oncology</i> , 2010, 1, 2-4.	0.6	9
245	Effective Dose from Stray Radiation for a Patient Receiving Proton Therapy for Liver Cancer. , 2009, 1099, 445-449.		2
246	Respiratory gating with EPID-based verification: the MDACC experience. <i>Physics in Medicine and Biology</i> , 2009, 54, 3379-3391.	1.6	22
247	Near-infrared narrow-band imaging of gold/silica nanoshells in tumors. <i>Journal of Biomedical Optics</i> , 2009, 14, 024044.	1.4	38
248	Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COXâ€“2, MMPâ€“9, VEGF and CXCR4 expression in an orthotopic mouse model. <i>International Journal of Cancer</i> , 2009, 125, 2187-2197.	2.3	183
249	Curcumin Modulates the Radiosensitivity of Colorectal Cancer Cells by Suppressing Constitutive and Inducible NF-Î²B Activity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 534-542.	0.4	166
250	Attempted Salvage Resection for Recurrent Gastric or Gastroesophageal Cancer. <i>Annals of Surgical Oncology</i> , 2009, 16, 42-50.	0.7	24
251	Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 836-47.	0.7	435
252	Spatial distribution, kinetics, signaling and cytokine production during homeostasis driven proliferation of CD4+ T cells. <i>Molecular Immunology</i> , 2009, 46, 2403-2412.	1.0	8

#	ARTICLE	IF	CITATIONS
253	The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma/x-ray sources. <i>Physics in Medicine and Biology</i> , 2009, 54, 4889-4905.	1.6	199
254	Modeling of plasmonic heating from individual gold nanoshells for near-infrared laser-induced thermal therapy. <i>Medical Physics</i> , 2009, 36, 4664-4671.	1.6	37
255	Modification of the cysteine residues in I $\kappa$ B $\kappa$ kinase and NF- $\kappa$ B (p65) by xanthohumol leads to suppression of NF- $\kappa$ B-regulated gene products and potentiation of apoptosis in leukemia cells. <i>Blood</i> , 2009, 113, 2003-2013.	0.6	154
256	The role of adjuvant radiation therapy in nonmetastatic gastric cancer: an evolving paradigm. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 33-5.	0.8	2
257	Proton Radiotherapy for Liver Tumors: Dosimetric Advantages Over Photon Plans. <i>Medical Dosimetry</i> , 2008, 33, 259-267.	0.4	83
258	Intensity Modulated Radiation Therapy (IMRT) for the Treatment of Squamous Cell Anal Cancer with Para-aortic Nodal Involvement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S266.	0.4	1
259	Role of Adjuvant Chemoradiation Therapy in Adenocarcinomas of the Ampulla of Vater. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 735-743.	0.4	68
260	Improving Soft-Tissue Contrast in Four-Dimensional Computed Tomography Images of Liver Cancer Patients Using a Deformable Image Registration Method. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 201-209.	0.4	13
261	Radiotherapy for Hepatocellular Carcinoma: An Overview. <i>Annals of Surgical Oncology</i> , 2008, 15, 1015-1024.	0.7	77
262	Does Neoadjuvant Treatment for Gastric Cancer Patients with Positive Peritoneal Cytology at Staging Laparoscopy Improve Survival?. <i>Annals of Surgical Oncology</i> , 2008, 15, 2684-2691.	0.7	98
263	Extrahepatic Bile Duct Adenocarcinoma: Patients at High-Risk for Local Recurrence Treated with Surgery and Adjuvant Chemoradiation Have an Equivalent Overall Survival to Patients with Standard-Risk Treated with Surgery Alone. <i>Annals of Surgical Oncology</i> , 2008, 15, 3147-3156.	0.7	90
264	Erratum to "In Vivo Detection of Gold Nanoshells in Tumors Using Diffuse Optical Spectroscopy". <i>IEEE Journal of Selected Topics in Quantum Electronics</i> , 2008, 14, 251-251.	1.9	2
265	Imaging Epidermal Growth Factor Receptor Expression <i>In vivo</i> : Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe. <i>Clinical Cancer Research</i> , 2008, 14, 731-741.	3.2	183
266	4D-CT imaging with synchronized intravenous contrast injection to improve delineation of liver tumors for treatment planning. <i>Radiotherapy and Oncology</i> , 2008, 87, 445-448.	0.3	61
267	Microscopy of gold nanoshells in tumors using two-photon induced photoluminescence. , 2008, , .		1
268	Modulation of in Vivo Tumor Radiation Response via Gold Nanoshell-Mediated Vascular-Focused Hyperthermia: Characterizing an Integrated Antihypoxic and Localized Vascular Disrupting Targeting Strategy. <i>Nano Letters</i> , 2008, 8, 1492-1500.	4.5	206
269	Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177. <i>Journal of Clinical Oncology</i> , 2008, 26, 5603-5609.	0.8	255
270	Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 2476-2483.	3.2	95



#	ARTICLE	IF	CITATIONS
271	Neutrophil Gelatinase-Associated Lipocalin: A Novel Suppressor of Invasion and Angiogenesis in Pancreatic Cancer. <i>Cancer Research</i> , 2008, 68, 6100-6108.	0.4	147
272	Curcumin Sensitizes Human Colorectal Cancer Xenografts in Nude Mice to $^{137}\text{Cs}$ -Radiation by Targeting Nuclear Factor- $\kappa\text{B}$ -Regulated Gene Products. <i>Clinical Cancer Research</i> , 2008, 14, 2128-2136.	3.2	201
273	Clinical benefit of palliative radiation therapy in advanced gastric cancer. <i>Acta Oncologica</i> , 2008, 47, 421-427.	0.8	96
274	Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head. <i>Journal of Clinical Oncology</i> , 2008, 26, 3487-3495.	0.8	441
275	Retrospective Study of Clinicopathologic Features and Prognosis of High-grade Neuroendocrine Carcinoma of the Esophagus. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1404-1411.	2.1	117
276	Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer. <i>Oncology Reports</i> , 2008, 19, 1071-7.	1.2	6
277	Back to basics: how natural products can provide the basis for new therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1753-1773.	1.9	115
278	TISSUE TRANSGLUTAMINASE DOWNREGULATION POTENTIATES GEMCITABINE EFFICACY AND BLOCKS PANCREATIC CANCER GROWTH AND METASTASIS IN VIVO. <i>Pancreas</i> , 2007, 35, 404-405.	0.5	1
279	Daily targeting of liver tumors: Screening patients with a mock treatment and using a combination of 2007, 34, 4591-4593.	1.6	5
280	Curcumin Potentiates Antitumor Activity of Gemcitabine in an Orthotopic Model of Pancreatic Cancer through Suppression of Proliferation, Angiogenesis, and Inhibition of Nuclear Factor- $\kappa\text{B}$ -Regulated Gene Products. <i>Cancer Research</i> , 2007, 67, 3853-3861.	0.4	561
281	VORINOSTAT RADIOSENSITIZES PANCREATIC CANCERS BY INHIBITING DNA REPAIR AND RADIATION-INDUCED EGFR AND NF- $\kappa\text{B}$ SIGNALING. <i>Pancreas</i> , 2007, 35, 398-399.	0.5	1
282	Gastrointestinal Complications Associated with Hepatic Arterial Yttrium-90 Microsphere Therapy. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 553-561.	0.2	163
283	Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 1588-1591.	0.2	34
284	Targeting cell signaling pathways for drug discovery: An old lock needs a new key. <i>Journal of Cellular Biochemistry</i> , 2007, 102, 580-592.	1.2	127
285	Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. <i>Cancer</i> , 2007, 109, 1750-1755.	2.0	294
286	Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. <i>Cancer</i> , 2007, 110, 47-55.	2.0	258
287	Correlation between internal fiducial tumor motion and external marker motion for liver tumors imaged with 4D-CT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 630-638.	0.4	122
288	Outcomes and Prognostic Factors in Primary Intraocular Lymphoma: A Multicenter Rare Cancer Network Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S534-S535.	0.4	0

#	ARTICLE	IF	CITATIONS
289	<i>In Vivo</i> Detection of Gold Nanoshells in Tumors Using Diffuse Optical Spectroscopy. IEEE Journal of Selected Topics in Quantum Electronics, 2007, 13, 1715-1720.	1.9	60
290	Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, 44-8.	0.8	2
291	The optimization of dose delivery for intraoperative high-dose-rate radiation therapy using curved HAM applicators. Radiotherapy and Oncology, 2006, 78, 207-212.	0.3	12
292	Clinical and Pathologic Predictors of Locoregional Recurrence, Distant Metastasis, and Overall Survival in Patients Treated With Chemoradiation and Mesorectal Excision for Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 219-224.	0.6	158
293	Conformal Radiotherapy of the Dominant Liver Metastasis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 562-567.	0.6	35
294	Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1192-1199.	0.4	88
295	Phase II study of capecitabine (Xeloda®) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 762-771.	0.4	110
296	84. International Journal of Radiation Oncology Biology Physics, 2006, 66, S49.	0.4	0
297	1067. International Journal of Radiation Oncology Biology Physics, 2006, 66, S167-S168.	0.4	0
298	Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer, 2006, 107, 2589-2596.	2.0	76
299	SU-FF-T-386: Respiratory Gating in the Treatment of Liver Tumors. Medical Physics, 2006, 33, 2134-2134.	1.6	1
300	SU-FF-J-82: Improving Soft Tissue Contrast in 4D CT Images of Liver Cancer Patients Using Deformable Image Registration Method. Medical Physics, 2006, 33, 2039-2039.	1.6	0
301	Radiosurgery for Cranial Base Chordomas and Chondrosarcomas. Neurosurgery, 2005, 56, 777-784.	0.6	136
302	Treatment Planning Study Using Protons for Liver Patients. International Journal of Radiation Oncology Biology Physics, 2005, 63, S205-S206.	0.4	1
303	Intraoperative radiotherapy using a mobile linear electron accelerator:. Journal of Applied Clinical Medical Physics, 2005, 6, 95-107.	0.8	12
304	TU-D-T-617-06: The Optimization of Dose Delivery for Intraoperative High-Dose-Rate Radiation Therapy Using Curved HAM Applicators. Medical Physics, 2005, 32, 2099-2099.	1.6	0
305	Choroid Plexus Papillomas: A Single Institutional Experience. Journal of Neuro-Oncology, 2004, 68, 49-55.	1.4	70
306	Long Term Outcome of Resected Choroid Plexus Papillomas. Is There a Role for Radiation?. Cancer Journal (Sudbury, Mass ), 2002, 8, 489.	1.0	1